Expression Of NF-κB, UPA And Bcl-2in Transitional Cell Carcinoma Of Bladder And Its Clinical Significance

Objective：To observe the expression of NF-κB p65，uPA and Bcl-2in bladdertransitional cell carcinoma tissue， and explore its relevance． Combination ofclinicopathological characteristics and to explore the role of development in bladdertransitional cell carcinoma of the three, in order to provide an important target for thetreatment of bladder cancer in the future.Methods：The expression of NF-κB p65and uPA、Bcl-2protein in40cases oftransitional cell carcinoma of bladder and10cases of normal bladder tissue weredetected by immunohistochemical technique，analyze its relationships with grade,stage, invasion and metastasis and recurrence, number, size，the correlation of NF-κBp65and uPA, Bcl-2.Results：(1). The positive expression rate of NF-κB p65in normal bladder tissue is20%(2/10), while the positive expression in bladder cancer is75%(30/40), significantlyhigher than the normal group, there are significant difference between the two groups(P<0.01). The positive expression rates of the BTCC pathological grades: low level(G1)46.2%(6/13), high level (G2/G3)88.9%(24/27), there are significant differencebetween the two groups (P<0.05). The positive expression rates of the non-muscularinvasive BTCC group (Tis~T1)57.9%(11/19), invasive BTCC group (T2~T4)90.5%(19/21), there are significant difference between the two groups (P<0.05). Thepositive expression rates of the non-lymph node metastasis and lymph nodemetastasis of BTCC are64.3%(18/28),100%(12/12), there are significant differencebetween the two groups (P<0.05). Recurrence group and primary group of BTCCpositive expression rates:66.7%(10/15),80%(20/25), there are not significantdifference between the two groups (P>0.05). Multiple group of BTCC positiveexpression rate:64.3%(9/14), single group of BTCC positive expression rate:80.8%(21/26), there are not significant difference between the two groups (P>0.05). Tumorsize≥3cm group of BTCC positive expression rate:70%(7/10), tumor size <3cmgroup of BTCC positive expression rate:76.7%(23/30), there are not significant difference between the two groups (P>0.05).(2). The positive expression rate of uPA in normal bladder tissue is10%(1/10),while the positive expression in bladder cancer is62.5%(25/40), significantlyhigher than the normal group, there are significant difference between the two groups(P<0.01). The positive expression rates of the BTCC pathological grades: low level(G1)38.5%(5/13), high level (G2/G3)74.1%(20/27), there are significant differencebetween the two groups (P<0.05). The positive expression rates of the non-muscularinvasive BTCC group (Tis~T1)42.1%(8/19), invasive BTCC group (T2~T4)80.9%(17/21), there are significant difference between the two groups (P<0.05). Thepositive expression rates of the non-lymph node metastasis and lymph nodemetastasis of BTCC are50%(14/28),91.7%(11/12), there are significant differencebetween the two groups (P<0.05). Recurrence group and primary group of BTCCpositive expression rates:60%(9/15),64%(16/25), there are not significant differencebetween the two groups (P>0.05). Multiple group of BTCC positive expression rate:71.4%(10/14), single group of BTCC positive expression rate:57.7%(15/26), thereare not significant difference between the two groups (P>0.05). Tumor size≥3cmgroup of BTCC positive expression rate:50%(5/10), tumor size <3cm group ofBTCC positive expression rate:66.7%(20/30), there are not significant differencebetween the two groups (P>0.05).(3). The positive expression rate of Bcl-2in normal bladder tissue is20%(2/10),while the positive expression in bladder cancer is67.5%(27/40), significantlyhigher than the normal group, there are significant difference between the two groups(P<0.05). The positive expression rates of the BTCC pathological grades: low level(G1)38.5%(5/13), high-level (G2/G3)81.5%(22/27), there are significant differencebetween the two groups (P<0.05). The positive expression rates of the non-muscularinvasive BTCC group (Tis~T1)47.4%(9/19), invasive BTCC group (T2~T4)85.7%(18/21), there are significant difference between the two groups (P<0.05). Thepositive expression rates of the non-lymph node metastasis and lymph nodemetastasis of BTCC are64.3%(18/28),75%(9/12), there are not significantdifference between the two groups (P>0.05). Recurrence group and primary group ofBTCC positive expression rates:73.3%(11/15),64%(16/25), there are not significant difference between the two groups (P>0.05). Multiple group of BTCC positiveexpression rate:57.1%(8/14), single group of BTCC positive expression rate:73.1%(19/26), there are not significant difference between the two groups (P>0.05). Tumorsize≥3cm group of BTCC positive expression rate:60%(6/10), tumor size <3cmgroup of BTCC positive expression rate:70%(21/30), there are not significantdifference between the two groups (P>0.05).(4). There was a significant positive correlation between expression of NF-κBp65and and uPA in bladder transitional cell carcinoma (r=0.388, P <0.05); Therewas a significant positive correlation between expression of NF-κB p65and Bcl-2inbladder transitional cell carcinoma (r=0.462, P <0.05).Conclusions：NF-κB p65，uPA and Bcl-2in bladder transitional cell carcinoma with highexpression and have relation to clinicopathological characteristics of the bladder transitional cellcarcinoma. NF-κB p65may promote the progress of bladder cancer by regulating uPA，Bcl-2.NF-κB p65，uPA and Bcl-2can be used as biomarkers to decide occurrence，invasion，metastasisand prognosis of bladder cancer.